Yuji Watanabe

Yuji Watanabe

Auto-generated profile, based on publicly available information

Yuji Watanabe

Laboratory for Clinical Microbiology, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, Japan

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
KTKazuki Takano
Kazuki Takano
DSDaishi Shimada
Daishi Shimada
SKShota Kashiwagura
Shota Kashiwagura
YKYasuhiro Kamioka
Yasuhiro Kamioka
MHMaya Hariu
Maya Hariu
Seki MasafumiSeki Masafumi
Seki Masafumi
Background: Mycobacterium abscessus frequently causes severe infections, yet its patho-physiological features and treatment regimens have not been established. Case Report: We present five cases of severe pneumonia due to Mycobacterium abscessus infection in Japan. All cases were diabetic patients, with possible acceleration to pneumonia due to co-infection with other microorganisms. However, following a short period of hospitalization and combination therapy with intravenous imipenem/cilastatin and amikacin, all the cases were successfully treated as outpatients with oral clarithromycin and sitafloxacin. Conclusion: M. abscessus infections can become severe in the presence of diabetes mellitus and co-infection with other chronic infectious organisms. Sitafloxacin might be a key drug in the treatment of M. abscessus infection in future.

1 February 2021 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YWYuji Watanabe
Yuji Watanabe
YKYasuhiro Kamioka
Yasuhiro Kamioka
Seki MasafumiSeki Masafumi
Seki Masafumi
Human rhinovirus (HRV) is known as one of the most important respiratory pathogens, and the clinical characteristics of HRV infection might be similar to those of coronavirus disease 2019 (COVID-19). We identified 11 HRV-infected patients by polymerase chain reactions of the HRV genes among 151 outpatients with fever. All nine adult patients had underlying diseases and finally improved with the appropriate treatment in this COVID-19 pandemic period. Differential diagnosis between HRV and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection will be needed to save lives and medical resources.

1 March 2022 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YWYuji Watanabe
Yuji Watanabe
HSHirohito Sano
Hirohito Sano
SKShuichi Konno
Shuichi Konno
YKYasuhiro Kamioka
Yasuhiro Kamioka
MHMaya Hariu
Maya Hariu
Seki MasafumiSeki Masafumi
Seki Masafumi
Background: Exophiala dermatitidis is an environmental black fungus that rarely causes respiratory infections, yet its pathophysiological features and treatment regimens have not been established. Case Series: Two cases of exacerbations of chronic bronchitis and sinusitis due to E. dermatitidis infection in Japan are presented. Both patients were women, and non-tuberculous Mycobacterium (NTM) infection was suspected based on chest radiological findings, but E. dermatitidis was detected from bronchial lavage fluid and nasal mucus, respectively. Both cases were successfully treated by antifungal agents such as liposomal amphotericin B, voriconazole, and itraconazole, but clarithromycin, rifampicin, ethambutol, and sitafloxacin for NTM were not effective. Conclusion: E. dermatitidis can become a respiratory pathogen, especially in patients with chronic sinobronchial syndrome.

1 July 2021 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
KTKazuki Takano
Kazuki Takano
YWYuji Watanabe
Yuji Watanabe
MHMaya Hariu
Maya Hariu
Seki MasafumiSeki Masafumi
Seki Masafumi
There is a concern that the spread of mutant strains of SARS-CoV-2 will increase the number of severe COVID-19 patients and weaken vaccine effectiveness in the world. The mutants of the spike region of SARS-CoV-2, such as N501Y, E484K, P681H, and deletion H69/V70 (del 69/70), were studied in 25 COVID-19 patients admitted from December 2020 to April 2021; there were no patients with N501Y and P681H, but nine patients had E484K alone. Their symptoms, laboratory data, and course of their disease were similar to those of the other patients with the non-mutant virus. One patient with del69/70 alone showed prolonged inflammation, viral excretion, and late exacerbation 18 days after onset. Del69/70 may be independently associated with evasion of immunity, as previously reported, and it is present in Japan.

1 June 2019 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
YWYuji Watanabe
Yuji Watanabe
NONozomi Oikawa
Nozomi Oikawa
MHMaya Hariu
Maya Hariu
MSMasayuki Seki
Masayuki Seki
Background: Small-colony variants of methicillin-resistant Staphylococcus aureus (SCV-MRSA) recently were described as slow-growing, thymidine-dependent strains; typically, SCV-MRSA were isolated from patients receiving sulfamethoxazole-trimethoprim, but detection of these strains frequently was delayed because of their small colony size and slow growth. Bacteremia cases due to SCV-MRSA sometimes become lethal when the initiation of treatment with intravenous anti-methicillin-resistant Staphylococcus aureus (MRSA) drugs starts too late. Methods: Here, we evaluated the use of general MRSA-specific agar plates in Japan, including MS-CFX, X-MRSA, and CHROMagar, for the efficient detection of SCV-MRSA, including the comparative detection efficiencies of these media for stock strains and clinical isolates. Results: Among the three MRSA-specific agar plates that were tested, X-MRSA and CHROMagar showed similar detection efficiencies for both 24 and 48 hrs culturing; in contrast, MS-CFS did not permit the detection of SCV-MRSA in stock strains. For clinical isolates of SCV-MRSA, X-MRSA plates permitted detection of the smallest and slowest-growing colonies of SCV-MRSA at 48 hrs of culturing; in contrast, CHROMagar and MS-CFX sometimes did not identify SCV-MRSA at 24 and 48 hrs. Conclusion: Optimization of media and incubation times will be necessary for efficient identification for SCV-MRSA, which would prevent delays in diagnosis and treatment with anti-MRSA drugs.

1 January 2018 in IDCases
Verified
Journal Article
Open access
Seki MasafumiSeki Masafumi
Seki Masafumi
BCBin Chang
Bin Chang
KOKengo Ohshima
Kengo Ohshima
YWYuji Watanabe
Yuji Watanabe
We present two adult cases of pneumococcal severe arthritis one case with, and other case without pericarditis those occurred in one season. Both cases eventually recovered, and the isolated S. pneumoniae strains were serotype 12F and penicillin susceptible. The patients were not elderly and had no medical history including pneumonia and vaccination. Although S. pneumoniae is a relatively rare causative pathogen of arthritis and/or pericarditis recently, a greater number of cases may be expected as a result of serotype conversion due to the increased use of pneumococcal conjugate vaccines in Japan.